{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carcinome corticosurrénalien : Questions médicales les plus fréquentes",
"headline": "Carcinome corticosurrénalien : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carcinome corticosurrénalien : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-04",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carcinome corticosurrénalien"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs corticosurrénaliennes",
"url": "https://questionsmedicales.fr/mesh/D000306",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs corticosurrénaliennes",
"code": {
"@type": "MedicalCode",
"code": "D000306",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.344.078.265"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carcinome corticosurrénalien",
"alternateName": "Adrenocortical Carcinoma",
"code": {
"@type": "MedicalCode",
"code": "D018268",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fassnacht",
"url": "https://questionsmedicales.fr/author/Martin%20Fassnacht",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Mainfranken, University of Würzburg, Würzburg, Germany; Central Laboratory, University Hospital Würzburg, Würzburg, Germany."
}
},
{
"@type": "Person",
"name": "Constanze Hantel",
"url": "https://questionsmedicales.fr/author/Constanze%20Hantel",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland; Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Germany."
}
},
{
"@type": "Person",
"name": "Katja Kiseljak-Vassiliades",
"url": "https://questionsmedicales.fr/author/Katja%20Kiseljak-Vassiliades",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Sandra Sigala",
"url": "https://questionsmedicales.fr/author/Sandra%20Sigala",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular & Translational Medicine, Section of Pharmacology, University of Brescia, 25123 Brescia, Italy."
}
},
{
"@type": "Person",
"name": "Jaydira Del Rivero",
"url": "https://questionsmedicales.fr/author/Jaydira%20Del%20Rivero",
"affiliation": {
"@type": "Organization",
"name": "Developmental Therapeutics Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy.",
"datePublished": "2023-10-09",
"url": "https://questionsmedicales.fr/article/37814272",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01381-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "An Unusual Presentation of Adrenocortical Carcinoma (ACC): Panic Attacks and Psychosis.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36037151",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12659/AJCR.937298"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36528469",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.arcmed.2022.12.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?",
"datePublished": "2022-08-03",
"url": "https://questionsmedicales.fr/article/35876101",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14656566.2022.2106128"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lived experience of people with adrenocortical carcinoma and associated adrenal insufficiency.",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35670031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/edm2.341"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs des glandes endocrines",
"item": "https://questionsmedicales.fr/mesh/D004701"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de la surrénale",
"item": "https://questionsmedicales.fr/mesh/D000310"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs corticosurrénaliennes",
"item": "https://questionsmedicales.fr/mesh/D000306"
},
{
"@type": "ListItem",
"position": 6,
"name": "Carcinome corticosurrénalien",
"item": "https://questionsmedicales.fr/mesh/D018268"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carcinome corticosurrénalien - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carcinome corticosurrénalien",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carcinome corticosurrénalien",
"description": "Comment diagnostique-t-on un carcinome corticosurrénalien ?\nQuels tests hormonaux sont utilisés pour le diagnostic ?\nQuelle imagerie est la plus courante pour ce cancer ?\nLe diagnostic peut-il être confirmé par une biopsie ?\nQuels signes cliniques peuvent indiquer un carcinome corticosurrénalien ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carcinome corticosurrénalien",
"description": "Quels sont les symptômes courants du carcinome corticosurrénalien ?\nLe carcinome corticosurrénalien cause-t-il des problèmes hormonaux ?\nComment le carcinome corticosurrénalien affecte-t-il le métabolisme ?\nY a-t-il des symptômes spécifiques chez les femmes ?\nLe carcinome corticosurrénalien peut-il causer des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carcinome corticosurrénalien",
"description": "Peut-on prévenir le carcinome corticosurrénalien ?\nQuels facteurs de risque sont associés à ce cancer ?\nLe mode de vie influence-t-il le risque de ce cancer ?\nLes examens réguliers aident-ils à la détection précoce ?\nY a-t-il des vaccins pour prévenir ce cancer ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carcinome corticosurrénalien",
"description": "Quels sont les traitements principaux pour ce cancer ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace pour ce type de cancer ?\nY a-t-il des traitements ciblés disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carcinome corticosurrénalien",
"description": "Quelles sont les complications possibles du carcinome corticosurrénalien ?\nLe carcinome peut-il entraîner des problèmes cardiovasculaires ?\nComment les déséquilibres hormonaux affectent-ils la santé ?\nY a-t-il un risque accru de récidive après traitement ?\nLe carcinome corticosurrénalien peut-il affecter la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carcinome corticosurrénalien",
"description": "Quels sont les principaux facteurs de risque du carcinome corticosurrénalien ?\nLes maladies génétiques augmentent-elles le risque ?\nL'âge est-il un facteur de risque ?\nLe sexe influence-t-il le risque de ce cancer ?\nLe stress a-t-il un impact sur le risque de carcinome ?",
"url": "https://questionsmedicales.fr/mesh/D018268?page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un carcinome corticosurrénalien ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, les tests hormonaux et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests hormonaux sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "On mesure les niveaux de cortisol, d'aldostérone et d'androgènes dans le sang."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est la plus courante pour ce cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tomodensitométrie (TDM) est souvent utilisée pour visualiser la tumeur."
}
},
{
"@type": "Question",
"name": "Le diagnostic peut-il être confirmé par une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie permet de confirmer la présence de cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer un carcinome corticosurrénalien ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypertension, la perte de poids et des changements hormonaux peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du carcinome corticosurrénalien ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, hypertension, prise de poids et changements d'humeur."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien cause-t-il des problèmes hormonaux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut entraîner un excès de cortisol, provoquant le syndrome de Cushing."
}
},
{
"@type": "Question",
"name": "Comment le carcinome corticosurrénalien affecte-t-il le métabolisme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer une résistance à l'insuline et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les femmes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent présenter des signes d'hyperandrogénie, comme l'hirsutisme."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien peut-il causer des douleurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales ou lombaires peuvent survenir en raison de la tumeur."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le carcinome corticosurrénalien ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à ce cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de ce cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de nombreux cancers, y compris celui-ci."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter des anomalies précoces."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ce cancer ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir le carcinome corticosurrénalien."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux pour ce cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut la chirurgie, la chimiothérapie et la radiothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours possible ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent la première option, mais dépend de l'étendue de la maladie."
}
},
{
"@type": "Question",
"name": "Quand la chimiothérapie est-elle recommandée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent utilisée pour les cas avancés ou inopérables du carcinome."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace pour ce type de cancer ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être utilisée pour réduire la taille de la tumeur ou traiter les métastases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblés disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés sont en cours d'étude, mais ne sont pas encore standardisés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du carcinome corticosurrénalien ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la propagation à d'autres organes et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Le carcinome peut-il entraîner des problèmes cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hypertension et d'autres problèmes cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les déséquilibres hormonaux affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des troubles métaboliques, des changements d'humeur et des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de récidive après traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de récidive est élevé, nécessitant un suivi régulier après traitement."
}
},
{
"@type": "Question",
"name": "Le carcinome corticosurrénalien peut-il affecter la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes et les traitements peuvent significativement impacter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du carcinome corticosurrénalien ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, certaines maladies génétiques et l'obésité sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des syndromes comme le syndrome de Li-Fraumeni augmentent le risque de ce cancer."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le carcinome corticosurrénalien est plus fréquent chez les adultes jeunes à moyens."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de ce cancer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes sont légèrement plus susceptibles de développer ce cancer que les hommes."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le risque de carcinome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que le stress soit un facteur de santé, son lien direct avec ce cancer n'est pas établi."
}
}
]
}
]
}
To summarize the clinical characteristics of children with adrenocortical carcinoma (ACC) and preliminarily explore the indications for and efficacy of neoadjuvant chemotherapy in certain patients....
The data of 49 children with adrenocortical tumors (ACT) in the past 15 years were retrospectively analyzed, and after pathology assessment using Weiss system grading, 40 children diagnosed with ACC w...
Forty patients (17 males, 23 females) with ACC were enrolled. Abnormal hormone levels were common in children with ACC (n = 31), and in terms of clinical presentation, sexual precocity was the most co...
In the diagnosis and treatment of pediatric ACC, a comprehensive endocrine evaluation is necessary to facilitate early diagnosis. Surgery and chemotherapy are important components of ACC treatment, an...
BACKGROUND Adrenocortical carcinoma (ACC) is a very rare disease, with an incidence of 1.02 per million population per year. The most commonly secreted hormone in ACC is cortisol, often presenting as ...
Numerous studies have suggested that ferroptosis plays an important regulatory role in cancer cell death. Nonetheless, the potential effects of ferroptosis regulators on the prognosis, the expression ...
Public ACC datasets were used to investigate the relationship between ferroptosis regulators and prognosis and clinical features. A ferroptosis scoring system was established for individual cases of A...
Twenty ferroptosis regulators were differentially expressed in ACC and 17 ferroptosis regulators were closely related to prognosis in ACC. A ferroptosis scoring system was developed based on ACSL4, FA...
Our study demonstrated that ferroptosis was significantly associated with prognosis, clinical characteristics, immune-checkpoint gene expression, and tumor microenvironment immune cell infiltration in...
Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in association with EDP (Etopo...
The activity of newer cytotoxic drugs, radioligands, targeted therapies, and immunotherapy, both in preclinical and clinical studies, will be reviewed in this paper....
ADIUVO trial revealed that the administration of adjuvant mitotane is not advantageous in patients with good prognosis. Future strategies are to intensify efforts in adjuvant setting in patients with ...
Adrenocortical carcinoma (ACC) is a rare cancer with an annual incidence of 0.7-2 cases per million population and 5-year survival of 31.2%. Adrenal insufficiency (AI) is a common and life shortening ...
To understand patients' lived experience of the condition, its treatment, care process, impact of AI on ACC wellbeing, self-care needs and support....
Systematic review of MEDLINE, EMBASES, CINAHL, PsycINFO and Open Grey for studies published until February 2021. All research designs were included. The findings underwent a thematic analysis and narr...
A total of 2837 citations were identified; 15 titles with cohort, cross-sectional, case series and case report study designs met the inclusion criteria involving 479 participants with adrenal insuffic...
ACC appears to have high impact on patients' wellbeing including the challenges with self-care and managing AI. Evidence is needed to understand patient experience from a qualitative perspective....
Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis and challenging management. The present study aimed to investigate the expression of programmed death ligand-1 (PD-L1) and V-d...
Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC). Yet, questions on the indication, dosage, and length of therapy ...
Adrenocortical carcinoma is a rare, but potentially lethal, malignancy that is usually detected as an incidental finding on abdominal imaging studies or owing to hormonal complications. This report re...
A 65-year-old White male physician presented with severe, bilateral pitting edema that extended from the toes to the thighs. It progressed over several months. He also experienced paroxysmal dyspnea. ...
Imaging of the abdomen and pelvis should be conducted in cases of unexplained leg edema. In this case, a large adrenal cancer compressed the vena cava. Iron deficiency followed resection of the large ...
BACKGROUND Adrenocortical carcinoma (ACC) is a rare malignancy associated with unfavorable prognosis. It is mainly diagnosed in the fifth or sixth decade of life. Symptoms of ACC are associated with h...
The pharmacological approach to adrenocortical carcinoma (ACC) is based on mitotane with/without etoposide, doxorubicin, and cisplatin, according to the disease stage. Considering the limited efficacy...